TrialBreast cancer research : BCR2012

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

Lynnette Fernández-Cuesta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.